The aim of the study is to assess the pharmacokinetic and pharmacodynamic properties of rocuronium and sugammadex and their clinical effect in the terms of both the relaxation of paralysed muscles (rocuronium) and the reversal of neuromuscular blockade (sugammadex) in children over 2 years of age undergoing general anesthesia for surgical procedures needing muscle relaxation for more than 30 minutes.

The study group was divided into three subgroups depending on the different doses of sugammadex. Group I received dose of 0.5 Mg/kg, Group II - 1.0 Mg/kg and Group III received dose of 2 Mg/kg of sugammadex. General anesthesia was performed among all included patients at the same way. During general anesthesia monitoring of TOF - Train-of-four, was used to assess the muscle relaxation force of rocuronium as well as the reversal of neuromuscular blockade by sugammadex. For this purpose, 1.5 ml of blood samples taken 8 times, were collected to determine the PKPD of the tested drugs, according to own protocol.

Inclusion Criteria:

• age 2-18 years
• ASA I-II
• qualification to surgival procedures requiring muscle relaxation for more than 30 minutes
• parental consent of children below 16 yrs and parental and child's consent if child was older than 16 yrs of age
• Bioethical Commission approvement No 161/17

Exclusion Criteria:

• ASA III and more
• age below 2 yrs
• lack of consent
• allergy to studied drugs
• less than 30 minutes of relaxation required

Children, aged 2-18 yrs, assessed according to American Society of Anesthesiologists (ASA) scale as I or II, qualified to surgical procedures requiring muscle relaxation for more than 30 minutes, and undergoing general anesthesia

PK and PD data (concentration/effect/time profiles) of individuals will be available

The data will be available in 4-6 months and available for 5 years

Scientists